@article {Gaughan2021.12.21.21267983, author = {Erin Gaughan and Tariq Sethi and Tom Quinn and Nikhil Hirani and Andrew Mills and Annya M. Bruce and Alison MacKinnon and Vassilios Aslanis and Feng Li and Richard O{\textquoteright}Connor and Richard A. Parker and John Norrie and James Dear and Ahsan R. Akram and Oliver Koch and Jie Wang-Jairaj and Robert J. Slack and Lise Gravelle and Bertil Lindmark and Kevin Dhaliwal}, title = {GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of safety, pharmacokinetics, and potential therapeutic value}, elocation-id = {2021.12.21.21267983}, year = {2021}, doi = {10.1101/2021.12.21.21267983}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Rationale High galectin-3 levels predict poor outcomes in patients with COVID-19. Galectin-3 activates monocytes and macrophages which are directly implicated in COVID-19 immunopathology and the cytokine storm. GB0139 is a potent thiodigalactoside galectin-3 inhibitor and may reduce the severe effects of the disease. We report safety and pharmacokinetics and pharmacodynamics of the inhaled galectin-3 inhibitor, GB0139, and assess clinical outcomes and key systemic inflammatory biomarkers in hospitalised patients with COVID-19 (ClinicalTrials.gov/EudraCT identifier: NCT04473053/2020-002230-32).Methods Adults with COVID-19 requiring oxygen, and with pneumonitis on x-ray, were randomised to receive standard of care (SOC; including dexamethasone; n=21) or SOC plus 10 mg GB0139 twice daily for 48 hours, then once daily for <=14 days (n=20).Results Patients aged 27{\textendash}87 years were enrolled from July 2020; the final patient completed the 90-day follow-up in April 2021. GB0139+SOC was well tolerated with no treatment-related serious adverse events reported. Incidences of adverse events were similar between treatment arms (40 with GB0139+SOC vs 35 with SOC). Plasma GB0139 was measurable in all patients after inhaled exposure, with moderate interpatient variability, and demonstrated target engagement with decreased circulating galectin (overall treatment effect post-hoc over days 2{\textendash}7: p=0{\textperiodcentered}0099 vs SOC). Rate of decline in fraction of inspired oxygen (\%) requirement was significantly greater in the GB0139+SOC arm with a posterior mean difference of -1{\textperiodcentered}51 (95\% highest posterior density: -2{\textperiodcentered}90, -0{\textperiodcentered}189) versus SOC. Plasma levels of biomarkers associated with inflammation, coagulopathy, major organ function and fibrosis showed a downward trend versus SOC.Conclusions GB0139+SOC was well tolerated and achieved clinically relevant plasma concentrations and target engagement. This, and the reduction in markers associated with inflammatory, coagulation, fibrosis, and reduction in inspired oxygen (\%) over SOC alone, indicates the therapeutic potential for inhaled GB0139 in hospitalised patients with COVID-19.Competing Interest StatementEG, TQ, AMB, FL, ROC, RAP, JN, JD, ARA, OK, KD: no conflicts of interest to disclose. TS, AMcK, VA, JW-J, RJS, LG, BL: employees of Galecto Inc. NH: received grants from Galecto Inc. AM: employee of Exploristics and received funding from Galecto Inc.Clinical TrialNCT04473053Funding StatementThis study was funded by LifeARCAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki and the principles of the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice. Independent ethics committee approval (Scotland A Research Ethics Committee: 20/SS/0066) was obtained prior to initiation of the study. The independent Data Monitoring Committee scrutinised accumulating data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOwnership of the data arising from this study resides with the study team. Scientific publications and the sharing of clinical data generated as part of this trial is crucial to better understanding COVID-19 and developing new treatments. As such, the results will be submitted for publication in a peer-reviewed journal. Data will be shared, with appropriate data sharing agreements, upon request.}, URL = {https://www.medrxiv.org/content/early/2021/12/21/2021.12.21.21267983}, eprint = {https://www.medrxiv.org/content/early/2021/12/21/2021.12.21.21267983.full.pdf}, journal = {medRxiv} }